These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35867960)
21. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Abramson JS; Bengston E; Redd R; Barnes JA; Takvorian T; Sokol L; Lansigan F; Armand P; Shah B; Jacobsen E; Martignetti R; Turba E; Metzler S; Patterson V; LaCasce AS; Bello CM Blood Adv; 2023 Apr; 7(7):1130-1136. PubMed ID: 36053786 [TBL] [Abstract][Full Text] [Related]
22. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505 [TBL] [Abstract][Full Text] [Related]
24. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience]. Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293 [TBL] [Abstract][Full Text] [Related]
25. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483 [TBL] [Abstract][Full Text] [Related]
30. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Sibon D; Bonnet C; Berriolo-Riedinger A; Edeline V; Parrens M; Damotte D; Coso D; André M; Meignan M; Rossi C J Clin Oncol; 2022 Apr; 40(10):1091-1101. PubMed ID: 34990281 [TBL] [Abstract][Full Text] [Related]
31. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414 [TBL] [Abstract][Full Text] [Related]
32. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994 [TBL] [Abstract][Full Text] [Related]
33. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857 [TBL] [Abstract][Full Text] [Related]
34. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998 [TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ; Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416 [TBL] [Abstract][Full Text] [Related]
36. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Borchmann P; Ferdinandus J; Schneider G; Moccia A; Greil R; Hertzberg M; Schaub V; Hüttmann A; Keil F; Dierlamm J; Hänel M; Novak U; Meissner J; Zimmermann A; Mathas S; Zijlstra JM; Fosså A; Viardot A; Hertenstein B; Martin S; Giri P; Scholl S; Topp MS; Jung W; Vucinic V; Beck HJ; Kerkhoff A; Unger B; Rank A; Schroers R; Zum Büschenfelde CM; de Wit M; Trautmann-Grill K; Kamper P; Molin D; Kreissl S; Kaul H; von Tresckow B; Borchmann S; Behringer K; Fuchs M; Rosenwald A; Klapper W; Eich HT; Baues C; Zomas A; Hallek M; Dietlein M; Kobe C; Diehl V; ; ; ; ; Lancet; 2024 Jul; 404(10450):341-352. PubMed ID: 38971175 [TBL] [Abstract][Full Text] [Related]
37. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569 [TBL] [Abstract][Full Text] [Related]